Thin melanomas

Clinics in Laboratory Medicine

Volumn 20, Issue 4, 2000, Pages 713-729

  King, R ^a   Googe, P B ^a   Mihm M C , Jr ^a  

^a Knoxville Dermatopathology Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER REGRESSION; DISEASE CLASSIFICATION; GROWTH CURVE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MELANOMA; METASTASIS; MITOSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REMISSION, SPONTANEOUS; SKIN NEOPLASMS;

EID: 0034484646     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Melanomas: Diagnosis and prognosis
2. The role of elective lymph node dissection in melanoma: Rationale, results and controversies
3. A comparison of prognostic factors worldwide
4. A multifactorial analysis of melanoma. Prognostic histopathological features comparing Clark's and Breslow's staging methods
5. A randomized prospective clinical trial of adjuvant C. parvum immnunotherapy in 260 patients with clinically localized melanoma (stage I): Prognostic factors analysis and preliminary results of immunotherapy
6. An analysis of prognostic factors in 8500 patients with cutaneous melanoma
7. A comparison of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia
8. A multifactorial analysis of melanoma:. II. Prognostic factors in patients with stage I (localized) melanoma
9. The prognostic significance of ulceration of cutaneous melanoma
10. Stereologic estimation of volume-weighted mean nuclear volume as a predictor of prognosis in "thin" malignant melanoma
11. Stereological estimates of nuclear volume in thin malignant melanomas
12. Thin malignant melanomas (< 1.5mm) with metastasis: A histological study and survival analysis
13. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
14. Experience of thin cutaneous melanomas (less than 0.76 mm and less than 0.85 mm thick) in a large plastic surgery unit: A 5 to 17 year follow-up
15. Recent incidence trends imply a non-metastasizing form of invasive melanoma
16. An analysis of a melanoma epidemic
17. Primary cutaneous melanoma: Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification
18. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
19. Prognosis of stage 1 melanoma of the skin
20. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma
21. Model predicting survival in stage I melanoma based on tumor progression
22. The histogenesis and biologic behavior of primary human malignant melanomas of the skin
23. Regression in thin malignant melanoma: Microscopic diagnosis and prognostic importance
24. Emergence of alpha 5 beta 1 fibronectin and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression
25. A multivariate analysis of prognostic factors for melanoma patients with lesions > 3.65 mm in thickness. The importance of revealing alternative Cox models
26. The natural break points for primary tumor thickness in clinical stage I melanoma
27. A prognostic model for clinical stage 1 melanoma of the trunk: Location near the midline is not an independent risk factor for recurrent disease
28. Analysis of the melanoma epidemic, both apparent and real: Data from the 1973 through 1994 surveillance, epidemiology, and end results program registry
29. Survival with malignant melanoma: A regression analysis of prognostic factors
30. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
31. Prognostic factors in cutaneous malignant melanoma in stage 1: A clinical, morphological and multivariate analysis
32. Clinicopathologic study of prognostic factors in cutaneous malignant melanoma
33. Review and current perspectives of cutaneous malignant melanoma
34. The regressing thin malignant melanoma: A distinctive lesion with metastatic potential
35. Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck
36. Survival among patients with clinical stage 1 cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981
37. In vivo human melanoma cytokine production: Inverse correlation of GM-CSF production with tumor depth
38. The relationship between risk of death from clinical stage I cutaneous melanoma and thickness of primary tumour: No evidence for steps in risk
39. Regression in malignant melanoma: A histologic feature without independent prognostic significance
40. Thin level IV malignant melanoma: A subset in which level is the major prognostic indicator
41. Prognostic index for malignant melanoma
42. Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults
43. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas
44. Malignant melanoma: Clinical and pathologic analysis of 93 cases: Is prophylactic lymph node dissection indicated?
45. Prognostic factors in thin cutaneous malignant melanoma
46. Thin cutaneous malignant melanomas (< or = 1.5 mm): Identification of risk factors indicative of progression
47. Cutaneous melanomas that defy conventional prognostic indicators
48. Prognosis in patients with thin malignant melanoma: Influence of regression
49. Staging of malignant melanoma by depth of invasion
50. Recurrence of thin melanoma: How effective if follow-up?
51. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR, and beta 3 integrin expression
52. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness
53. Recurrence potential of thin primary melanomas
54. National Institutes of health consensus development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27- 29, 1992
55. Expression of interleukin- 8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma
56. Biologic behavior of thin malignant melanomas with regressive changes
57. A study of thin (<1.5 mm) malignant melanomas with poor prognosis
58. Malignant melanomas of the skin
59. Factors influencing survival in melanoma
60. Thin malignant melanomas with regression and metastases
61. Histologic prognostic indicators in cutaneous malignant melanoma
62. Regression and other factors of prognostic interest in malignant melanoma
63. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours
64. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels
65. IL- 8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor
66. Low- and high-risk malignant melanoma: II. Multivariate analyses for a prognostic classification
67. Prognostic index in malignant melanoma
68. Time to recurrence varies inversely with thickness in clinical stage I cutaneous melanoma
69. The thin malignant melanoma: Changing patterns of epidemiology and treatment
70. Malignant melanoma: Influence of site of lesion and age of patient in female superiority in survival
71. Lethal "thin" malignant melanoma: Identifying patients at risk
72. Spontaneous regression of primary malignant melanomas with regional metastases
73. An evaluation of vertical growth in thin superficial spreading melanomas by sequential serial microscopic sections
74. Partial regression in thin primary cutaneous malignant melanomas clinical stage I: A study of 486 cases
75. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases
76. A computerized mathematical model and scoring system for predicting outcome in patients with localized melanoma
77. Prognostic significance of p53 overexpression in thin melanomas
78. Trends in tumour characteristics and survival of malignant melanoma 1960-84: A population-based study in Sweden
79. Metastases of thin melanomas
80. Stage I melanoma of the skin: Evaluation of prognosis according to histologic characteristics
81. Thin melanomas with unusual aggressive behavior: A report on nine cases
82. Malignant melanoma: A multivariate analysis of prognostic factors
83. Expression of p53 protein in malignant melanoma: Clinicopathological and prognostic implications
84. Expression of p 53 protein in malignant melanomas as a prognostic indicator